It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Lipid nanoparticles (LNPs) play a crucial role in addressing genetic disorders, and cancer, and combating pandemics such as COVID-19 and its variants. Yet, the ability of LNPs to effectively encapsulate large-size DNA molecules remains elusive. This is a significant limitation, as the successful delivery of large-size DNA holds immense potential for gene therapy. To address this gap, the present study focuses on the design of PEGylated LNPs, incorporating large-sized DNA, departing from traditional RNA and ionizable lipids. The resultant LNPs demonstrate a unique particle morphology. These particles were further engineered with a DNA coating and plasma proteins. This multicomponent bionanoconstruct exhibits enhanced transfection efficiency and safety in controlled laboratory settings and improved immune system evasion in in vivo tests. These findings provide valuable insights for the design and development of bionanoarchitectures for large-size DNA delivery, opening new avenues for transformative gene therapies.
Encapsulation of large-size DNA molecules into lipid nanoparticles (LNPs) remains challenging. Here, the authors engineer PEGylated LNPs with DNA and plasma proteins to improve the delivery of large DNA molecules, enhancing the gene therapy potential.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details











1 Sapienza University of Rome, Department of Molecular Medicine, Rome, Italy (GRID:grid.7841.a)
2 Laboratory affiliated to Istituto Pasteur Italia-Fondazione Cenci Bolognetti, Department of Medico-Surgical Sciences and Biotechnology, Sapienza University of Rome, Latina, Italy (GRID:grid.7841.a)
3 Sapienza University of Rome, Department of Radiological, Oncological and Pathological Sciences, Rome, Italy (GRID:grid.7841.a)
4 Scuola Normale Superiore, NEST, Pisa, Italy (GRID:grid.6093.c) (ISNI:0000 0001 2207 3110)
5 Sapienza University of Rome, Department of Chemistry, Rome, Italy (GRID:grid.7841.a)
6 Sapienza University of Rome, Unit of Histology and Medical Embryology, Department of Anatomy, Histology, Forensic Medicine and Orthopedics, Rome, Italy (GRID:grid.7841.a)
7 Graz University of Technology, Institute of Inorganic Chemistry, Graz, Austria (GRID:grid.410413.3) (ISNI:0000 0001 2294 748X)
8 Sapienza University of Rome, Department of Basic and Applied Sciences for Engineering and Center for Nanotechnology Applied to Engineering (CNIS), Rome, Italy (GRID:grid.7841.a)